Recordati Delisting Means Privatization for Italian Pharma Group
· fitness
The Privatization Prescription: What Recordati’s Delisting Means for Healthcare M&A
Recordati, a 100-year-old Italian pharmaceutical group, is set to disappear from public markets after a €10.73 billion cash bid led by CVC Capital Partners and Groupe Bruxelles Lambert was launched. The consortium’s offer of €51.29 per share represents a substantial premium over Recordati’s share price, factoring in a recent dividend payment that boosts the total economic package to an implied €52 per share.
The deal marks a significant milestone for private equity investment in Europe’s healthcare sector. CVC’s involvement is not new; the consortium first invested in Recordati in 2018 by purchasing the founding family’s equity and currently holds a significant stake through its Rossini investment vehicle. This structural advantage has given CVC a clear path to privatization, with GBL stepping up as a co-control partner and injecting cash from its €13.3 billion portfolio.
The implications of Recordati’s delisting extend far beyond the company itself. As one of Europe’s largest healthcare buyouts in recent years, it sets a precedent for private equity players seeking to capitalize on rare-disease portfolios and dealmaking pipelines. By pursuing these opportunities outside public markets, private equity firms can sidestep short-term volatility and focus on long-term value creation.
Private equity investment has increasingly turned towards sectors like biotechnology and pharmaceuticals, where companies can benefit from patient capital and strategic guidance. As a result, we’re witnessing a gradual shift away from public markets, where companies are under pressure to deliver quarterly returns. This trend is not unique to Recordati or the European healthcare sector.
The involvement of elite co-investors like the Abu Dhabi Investment Authority and Canada’s CPP Investment Board adds another layer of complexity to the deal. Their participation underscores the increasingly global nature of private equity investment in Europe, where cross-border deals are becoming more common.
Recordati’s delisting is also a test case for European corporate governance structures. The company’s board has faced intense scrutiny following CVC’s initial offer, with some shareholders questioning the adequacy of the premium offered and the motivations behind the privatization. As the deal nears completion, it remains to be seen whether the consortium will meet the 66.67% threshold required for a squeeze-out.
The European Commission has been vocal about its concerns regarding private equity involvement in strategic sectors like healthcare. As Recordati’s delisting proceeds, it will be crucial to monitor whether this deal sets a precedent for future mergers and acquisitions. With CVC at the helm, we can expect the consortium to continue pursuing opportunities in rare-disease portfolios and dealmaking pipelines – outside public markets, where they believe value creation is more sustainable.
Investors will be watching closely as the dust settles on Recordati’s delisting, eager to see whether this trend gains momentum. Will other healthcare companies follow suit, seeking the perceived benefits of private equity backing? The answer lies in understanding the underlying drivers of corporate strategy and investor behavior – a delicate dance between short-term returns and long-term value creation.
The Recordati deal is just one chapter in an ongoing story about the evolving role of private equity in Europe’s healthcare sector. As we continue to navigate this complex landscape, it’s essential to separate hype from reality and consider the structural implications of privatization on corporate governance, investment strategies, and innovation in the sector.
Reader Views
- DRDevon R. · former athlete
This Recordati deal is just another example of private equity's stranglehold on Europe's pharma sector. What's striking is how GBL and CVC are essentially buying out a company that was already partially owned by their affiliates. This lack of transparency raises red flags about the true value being extracted from these M&A deals. One wonders what will become of Recordati's research pipelines, which often rely on public funding to stay afloat, once it's been privatized and subject to short-term financial pressures.
- CTCoach Tara M. · strength coach
While Recordati's privatization may seem like just another big buyout, it marks a significant shift in how private equity firms approach healthcare M&A. As someone who works with clients on their own strategic acquisitions, I think we need to consider the implications of this deal for small- and mid-sized biotechs that rely on public markets to raise capital. With more companies like Recordati exiting public hands, where will these fledgling businesses turn for investment? The private equity firms involved in this deal may be creating a lucrative opportunity for themselves, but they're also shrinking the pool of potential buyers for emerging companies.
- TGThe Gym Desk · editorial
This Recordati delisting is less about private equity's entry into European healthcare and more about its stranglehold on the sector. CVC Capital Partners' cozy relationship with the company has given them a clear path to privatization, while public markets are left footing the bill for regulatory compliance. As more companies succumb to these buyout tactics, we should be wary of sacrificing long-term research and development for short-term profits, especially in an industry where innovation is paramount. The true cost of this deal may only become apparent years from now.